IgA Nephropathy Upon completion of this module, learners will be able to: 1. Explain the 4 hit hypothesis of the pathogenesis of IgA nephropathy 2. Compare and contrast mechanism of action, side effects, and role in therapy for new treatments for IgA nephropathy (budesonide delayed release capsules, sparsentan, and iptacopan) 3. Describe evidence for new treatments for IgA nephropathy (budesonide delayed release capsules, sparsentan, and iptacopan) 4. Apply updated guideline to a patient case in choosing the appropriate treatment from either traditional or new targeted treatments, or a combination of traditional and new treatments
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 650 Childrens Rehab
Pricing
100% of listed courses are free
16 of 16 courses listed here are free.
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Online course / module
- includes Case study / clinical scenario
- Credit · Up to 1 credit
-
ReleasedApr 8, 2026
-
Last day to claim creditApr 9, 2029 2 years left
-
Advancing Kidney Health through Optimal Medication Management +1 AKHOMM: Primer on Immunosuppressants used in Glomerular Disease, Part 1 Basics and Traditional Immunosuppressants
-
Advancing Kidney Health though Optimal Medication Management +1 AKHOMM: Primer on Immunosuppressants used in Glomerular Disease, Part 2: Indications and Novel Agents
-
Advancing Kidney Health through Optimal Medication Management (AKHOMM) +1 AKHOMM: Clinical Approach and Emerging Therapeutics for Focal Segmental Glomerulosclerosis (FSGS)
